These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 22914736)
21. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M; Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913 [TBL] [Abstract][Full Text] [Related]
23. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. Suthoff ED; Bonafede M; Limone B; O'Callaghan L; Sawicki GS; Wagener JS J Med Econ; 2016 Sep; 19(9):845-51. PubMed ID: 27074519 [TBL] [Abstract][Full Text] [Related]
24. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related]
25. Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation. Yousef S; Solomon GM; Brody A; Rowe SM; Colin AA Chest; 2015 Mar; 147(3):e79-e82. PubMed ID: 25732475 [TBL] [Abstract][Full Text] [Related]
26. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein]. Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675 [TBL] [Abstract][Full Text] [Related]
27. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation. Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139 [TBL] [Abstract][Full Text] [Related]
29. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis. Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688 [No Abstract] [Full Text] [Related]
30. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242 [No Abstract] [Full Text] [Related]
31. Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation. Wherry K; Williamson I; Chapman RH; Kuntz KM Value Health; 2020 Oct; 23(10):1332-1339. PubMed ID: 33032777 [TBL] [Abstract][Full Text] [Related]
32. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor. Ronan NJ; Einarsson GG; Twomey M; Mooney D; Mullane D; NiChroinin M; O'Callaghan G; Shanahan F; Murphy DM; O'Connor OJ; Shortt CA; Tunney MM; Eustace JA; Maher MM; Elborn JS; Plant BJ Chest; 2018 Feb; 153(2):395-403. PubMed ID: 29037527 [TBL] [Abstract][Full Text] [Related]
33. Sweat chloride is not a useful marker of clinical response to Ivacaftor. Barry PJ; Jones AM; Webb AK; Horsley AR Thorax; 2014 Jun; 69(6):586-7. PubMed ID: 24258833 [TBL] [Abstract][Full Text] [Related]
34. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Sawicki GS; Dasenbrook E; Fink AK; Schechter MS Ann Am Thorac Soc; 2015 Aug; 12(8):1146-52. PubMed ID: 26073026 [TBL] [Abstract][Full Text] [Related]
35. Cystic fibrosis in the era of genomic medicine. Milla CE Curr Opin Pediatr; 2013 Jun; 25(3):323-8. PubMed ID: 23652683 [TBL] [Abstract][Full Text] [Related]
36. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis. Grasemann H; Gonska T; Avolio J; Klingel M; Tullis E; Ratjen F J Cyst Fibros; 2015 Nov; 14(6):727-32. PubMed ID: 26168933 [TBL] [Abstract][Full Text] [Related]
37. Ivacaftor potentiation of multiple CFTR channels with gating mutations. Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084 [TBL] [Abstract][Full Text] [Related]
38. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience. Dagan A; Cohen-Cymberknoh M; Shteinberg M; Levine H; Vilozni D; Bezalel Y; Bar Aluma BE; Sarouk I; Ashkenazi M; Lavie M; Tsabari R; Blau H; Kerem E; Bentur L; Efrati O; Livnat G Respir Med; 2017 Oct; 131():225-228. PubMed ID: 28947035 [TBL] [Abstract][Full Text] [Related]
39. Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report. Lenherr N; Lurà M; Trachsel D; Latzin P; Hammer J BMC Pulm Med; 2015 Oct; 15():123. PubMed ID: 26474553 [TBL] [Abstract][Full Text] [Related]
40. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Jones AM; Barry PJ Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]